Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
PROK
Stock Latest News
Company Announcements
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
3d ago
PROK
Premium
Ratings
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
4d ago
PROK
Premium
The Fly
ProKidney reports Q4 EPS (52c), consensus (15c)
4d ago
PROK
Premium
Ratings
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
2M ago
PROK
Premium
Ratings
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
2M ago
PROK
Premium
Company Announcements
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
2M ago
8K
PROK
Premium
Ratings
Advancing Rilparencel in Diabetic CKD: De-Risked PROACT 1 Trial Design and Strong Enrollment Support Buy Rating on ProKidney
2M ago
PROK
Premium
Company Announcements
ProKidney Advances Rilparencel Program and Manufacturing Expansion
2M ago
8K
PROK
Premium
The Fly
ProKidney initiated with a Buy at H.C. Wainwright
3M ago
PROK
Premium
Pre-Earnings
PROK Upcoming Earnings Report: What to Expect?
4M ago
PROK
Premium
The Fly
ProKidney reports Q3 EPS (12c), consensus (14c)
4M ago
PROK
Premium
The Fly
ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
5M ago
PROK
Premium
Company Announcements
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
5M ago
PROK
Premium
Company Announcements
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
5M ago
PROK
Premium
Company Announcements
Prokidney’s Long-Term Study on Renal Therapy: A Potential Game Changer for CKD
5M ago
PROK
Premium
Company Announcements
ProKidney Sells Greensboro Property for $19.1 Million
5M ago
8K
PROK
Premium
Ratings
ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook
7M ago
PROK
Premium
Company Announcements
ProKidney Corp. Reports Q2 2025 Financial Results
7M ago
PROK
Premium
The Fly
ProKidney reports Q2 EPS (13c), consensus (14c)
7M ago
PROK
Premium
The Fly
Prokidney Corp options imply 15.7% move in share price post-earnings
7M ago
PROK
Premium
The Fly
Prokidney Corp options imply 13.0% move in share price post-earnings
8M ago
PROK
Premium
Company Announcements
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment
8M ago
PROK
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
